WO2006131651A3 - Composition a base d'une avermectine et d’ηydrocortisone notamment pour le traitement de la rosacée - Google Patents

Composition a base d'une avermectine et d’ηydrocortisone notamment pour le traitement de la rosacée Download PDF

Info

Publication number
WO2006131651A3
WO2006131651A3 PCT/FR2006/001299 FR2006001299W WO2006131651A3 WO 2006131651 A3 WO2006131651 A3 WO 2006131651A3 FR 2006001299 W FR2006001299 W FR 2006001299W WO 2006131651 A3 WO2006131651 A3 WO 2006131651A3
Authority
WO
WIPO (PCT)
Prior art keywords
avermectin
hydrocortisone
roracea
treatment
based composition
Prior art date
Application number
PCT/FR2006/001299
Other languages
English (en)
Other versions
WO2006131651A2 (fr
Inventor
Alexandre Kaoukhov
Colette Pernin
Original Assignee
Galderma Sa
Alexandre Kaoukhov
Colette Pernin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Sa, Alexandre Kaoukhov, Colette Pernin filed Critical Galderma Sa
Priority to BRPI0612935-8A priority Critical patent/BRPI0612935A2/pt
Priority to CA002610761A priority patent/CA2610761A1/fr
Priority to EP06764751A priority patent/EP1898932A2/fr
Publication of WO2006131651A2 publication Critical patent/WO2006131651A2/fr
Publication of WO2006131651A3 publication Critical patent/WO2006131651A3/fr
Priority to US12/000,186 priority patent/US20080176928A1/en
Priority to US12/394,217 priority patent/US20090163455A1/en
Priority to US12/843,372 priority patent/US20110178049A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à une composition pharmaceutique, notamment dermatologique, comprenant, dans un milieu physiologiquement acceptable, au moins un composé de la famille des avermectines et de l'hydrocortisone ainsi que son utilisation pour la fabrication d'un médicament destiné au traitement d'affections de la peau, notamment la rosacée.
PCT/FR2006/001299 2005-06-10 2006-06-08 Composition a base d'une avermectine et d’ηydrocortisone notamment pour le traitement de la rosacée WO2006131651A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0612935-8A BRPI0612935A2 (pt) 2005-06-10 2006-06-08 composição farmacêutica e uso
CA002610761A CA2610761A1 (fr) 2005-06-10 2006-06-08 Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
EP06764751A EP1898932A2 (fr) 2005-06-10 2006-06-08 Composition a base d'une avermectine et d ydrocortisone notamment pour le traitement de la rosacée
US12/000,186 US20080176928A1 (en) 2005-06-10 2007-12-10 Avermectin/hydrocortisone compositions for treating afflictions of the skin, E.G., rosacea
US12/394,217 US20090163455A1 (en) 2005-06-10 2009-02-27 Avermectin/hydrocortisone compositions for treating afflictions of the skin, e.g., rosacea
US12/843,372 US20110178049A1 (en) 2005-06-10 2010-07-26 Avermectin/hydrocortisone compositions for treating afflictions of the skin. e.g., rosacea

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0505919A FR2886852B1 (fr) 2005-06-10 2005-06-10 Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR0505919 2005-06-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/000,186 Continuation US20080176928A1 (en) 2005-06-10 2007-12-10 Avermectin/hydrocortisone compositions for treating afflictions of the skin, E.G., rosacea

Publications (2)

Publication Number Publication Date
WO2006131651A2 WO2006131651A2 (fr) 2006-12-14
WO2006131651A3 true WO2006131651A3 (fr) 2007-09-13

Family

ID=35169321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/001299 WO2006131651A2 (fr) 2005-06-10 2006-06-08 Composition a base d'une avermectine et d’ηydrocortisone notamment pour le traitement de la rosacée

Country Status (6)

Country Link
US (3) US20080176928A1 (fr)
EP (1) EP1898932A2 (fr)
BR (1) BRPI0612935A2 (fr)
CA (1) CA2610761A1 (fr)
FR (1) FR2886852B1 (fr)
WO (1) WO2006131651A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085753A1 (fr) * 2009-01-23 2010-07-29 Jr Chem, Llc Traitements pour l'acné rosacée et trousses médicales pour les mettre en pratique
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US9233118B2 (en) 2013-07-08 2016-01-12 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
WO2016096795A1 (fr) * 2014-12-15 2016-06-23 Galderma Sa Composé de la famille des avermectines utilisable en vue du traitement et/ou de la prévention de dermatoses inflammatoires
WO2016096797A1 (fr) * 2014-12-15 2016-06-23 Galderma Sa Composé de la famille des avermectines associé à un autre composé actif en vue du traitement et/ou de la prévention des dermatoses inflammatoires

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265571A (en) * 1965-04-08 1966-08-09 Barnes Hind Pharm Inc Thixotropic acne vulgaris composition
WO2004093886A1 (fr) * 2003-04-24 2004-11-04 Galderma S.A. Formulation a usage topique d'ivermectine pour le traitement de conditions dermatologiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265511A (en) * 1963-06-12 1966-08-09 Honeywell Inc Electroless plating
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6399652B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265571A (en) * 1965-04-08 1966-08-09 Barnes Hind Pharm Inc Thixotropic acne vulgaris composition
WO2004093886A1 (fr) * 2003-04-24 2004-11-04 Galderma S.A. Formulation a usage topique d'ivermectine pour le traitement de conditions dermatologiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GO TH M J H ET AL: "Comparative study of triamcinolone acetonide and hydrocortisone 17 butyrate in rosacea with special regard to the rebound phenomenon", DERMATOLOGICA 1976, vol. 152, no. Sup 1, 1976, pages 239 - 246, XP009056333 *
KOH M S ET AL: "An unusual cause of pulmonary haemorrhage in a patient with rheumatoid arthritis.", ANNALS OF THE ACADEMY OF MEDICINE, SINGAPORE. MAY 2004, vol. 33, no. 3, May 2004 (2004-05-01), pages 365 - 367, XP009056305, ISSN: 0304-4602 *
SNEDDON I: "A TRIAL OF HYDROCORTISONE BUTYRATE IN THE TREATMENT OF ROSACEA AND PERI ORAL DERMATITIS", BRITISH JOURNAL OF DERMATOLOGY, vol. 89, no. 5, 1973, pages 505 - 508, XP009056331, ISSN: 0007-0963 *
WAY S C ET AL: "Topical hydrocortisone therapy in acne rosacea and acne vulgaris.", NEW YORK STATE JOURNAL OF MEDICINE. 1 NOV 1957, vol. 57, no. 21, 1 November 1957 (1957-11-01), pages 3463 - 3465, XP009056332, ISSN: 0028-7628 *

Also Published As

Publication number Publication date
WO2006131651A2 (fr) 2006-12-14
FR2886852B1 (fr) 2007-11-23
CA2610761A1 (fr) 2006-12-14
US20110178049A1 (en) 2011-07-21
BRPI0612935A2 (pt) 2010-12-07
US20080176928A1 (en) 2008-07-24
EP1898932A2 (fr) 2008-03-19
FR2886852A1 (fr) 2006-12-15
US20090163455A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
WO2007002572A3 (fr) Nattokinase pour reduire la viscosite du sang total
WO2007050784A3 (fr) Traitement a base de combinaisons de medicaments a rapport fixe pour le traitement de tumeurs solides
WO2006037031A3 (fr) Formulations et procedes destines au traitement de maladies inflammatoires
WO2009034559A3 (fr) Procédé cosmétique pour un traitement esthétique et/ou de réparation de la peau
WO2007128817A3 (fr) Dérivé insulinique
WO2006131651A3 (fr) Composition a base d'une avermectine et d’ηydrocortisone notamment pour le traitement de la rosacée
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
WO2006008639A8 (fr) Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r
WO2009040420A3 (fr) Utilisation d'un monoterpène pour accroître une réparation tissulaire
WO2007119028A3 (fr) Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
WO2008006839A3 (fr) Combinaisons de flibansérine avec de la caféine, procédé pour leur préparation et utilisation de celles-ci en tant que médicaments
WO2006093784A3 (fr) Antibiotiques, ainsi que combinaisons d'antibiotiques et de formulations d'agents de soulagement symptomatique
WO2006095029A3 (fr) Conjugues di-polymere-proteine et procedes de preparation de ceux-ci
WO2006138608A3 (fr) Compositions pharmaceutiques et leur utilisation
WO2004071382A3 (fr) Heterocycles substitues
IL197575A (en) A method for removing adult stem cells from the blood, using them to prepare drugs for the treatment of lesions, and a medical preparation containing these adult GES cells
WO2007093880A3 (fr) Nouveaux dérivés d'indolopyrone et leur procédé de préparation
WO2007144169A3 (fr) Dérivés d'entacapone
WO2008022345A3 (fr) Compositions et procédés pour inhiber le cytochrome p450
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
WO2005046593A3 (fr) Methodes et compositions faisant appel a du thalidomide pour le traitement et pour la gestion de cancers et d'autres maladies
WO2008119097A8 (fr) Agent pharmaceutique contre les démangeaisons et la douleur
BRPI0607976A2 (pt) composição farmacêutica e uso de uma composição
WO2005039578A3 (fr) Utilisation de derive desoxynojirimycine ou de l'un de ses sels pharmaceutiquement admis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006764751

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2610761

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2006764751

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0612935

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071024